From Name:
From Email:
To Name:
To Email:

Optional Message:


Anti-cavity drug in C3 Jian's phase 2 clinical trial targets elimination of streptococcus mutans

from Dentistry IQ

C3 Jian Inc., a private company focused on providing improved oral healthcare, recently announced that it has successfully completed the initial phase two clinical trial for its novel drug, C16G2. The company's drug targets the specific elimination of streptococcus mutans, the acid producing bacterium associated with dental caries or tooth decay. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063